

Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038–1044]



Sebastian Meltzer^{*}, Tonje Bjørntrø^{*,†}, Lars Gustav Lyckander[‡], Kjersti Flatmark^{†,§,||}, Svein Dueland[¶], Rampradeep Samiappan[#], Christin Johansen^{*}, Erta Kalanxhi^{*}, Anne Hansen Ree^{*,†} and Kathrine Røe Redalen^{*,††}

^{*}Department of Oncology, Akershus University Hospital, Lørenskog, 1478, Norway; [†]Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway; [‡]Department of Pathology, Akershus University Hospital, Lørenskog, 1478, Norway; [§]Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, 0424, Norway; ^{||}Department of Tumor Biology, Oslo University Hospital, Oslo, 0424, Norway; [¶]Department of Oncology, Oslo University Hospital, Oslo, 0424, Norway; [#]Department of Bioscience and Nutrition, Karolinska Institutet, Huddinge, SE-141 83, Sweden; ^{††}Department of Physics, Norwegian University of Science and Technology, Trondheim, 7491, Norway

The authors regret to inform that we recently discovered an error in this article. One of the exosomal miRNAs that was detected in all patient samples, miR-29a-3p, was in the article erroneously labeled and described as being significantly differently expressed between two patient groups (TRG 1 *versus* TRG 2-3) within the investigation and validation cohorts. Fortunately, miR-29a-3p had not been selected for down-stream analyses, averting consequential errors within the study.

Below follows a list of edits pertaining to the correct labeling of *miR-29a-3p as not being differently expressed between the patient groups TRG 1 and TRG 2-3 in the investigation and validation cohorts*. The edits are **in bold and underlined**.

We sincerely regret if our inadvertent mistake has caused confusions. The conclusions drawn from the experiments are not affected.

1. *Results, the first and second paragraphs*, should read:

Of the initial 372 exosomal miRNAs tested in the investigation cohort, 44 were detected in all samples, with an average of 135

miRNAs per sample (Supplementary Table 2 and Supplementary Table 3A). Analysis with SAM uncovered 37 miRNAs with significantly altered expression according to N- or M-status, or TRG (Supplementary Table 1). Of these, **five** miRNAs with a strong probability of relation to M-status and TRG were verified using single parameter Student's *t* test (Supplementary Table 1).

The observed significant associations presented in Figure 1 show that **there was no difference in** expression of miR-29a-3p **between TRG groups**, and low levels of miR-301a-3p were found in patients with poor tumor response (TRG 2-3) to neoadjuvant therapy in the investigation cohort. Further, miR-141-3p, miR-375, miR-423-5p, and miR-431-3p were all found to be higher expressed in patients with synchronous liver metastasis. **The top** six miRNAs were selected for validation along with seven miRNAs as reference for normalization.

2. The corrected *Figure 1* is shown below, where **the erroneous asterisks in panel E have been removed**. This does not affect the figure legend, which reads as in the published article version.


Address all correspondence to: Sebastian Meltzer, MD, PhD, Akershus University Hospital, Department of Oncology, Lørenskog, 1478, Norway. E-mail: E-mail: Sebastian.meltzer@medisin.uio.no

DOI of original article: <http://dx.doi.org/10.1016/j.tranon.2019.04.014>

© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1936-5233/19

<https://doi.org/10.1016/j.tranon.2019.09.005>



3. *Supplementary Table 1* miRNA selection overview. In the investigation cohort, 36 miRNAs had significantly altered expression according to node (N) or metastatic (M)-status, or tumor regression grade (TRG) noted as fold change between the groups in the

Significance Analysis of Microarrays (SAM) software. Of these 36, **five** were verified using single parameter Student's *t* test. We selected **the top** six for validation, and added another 7 miRNAs with the highest stability to validate in the independent validation cohort.

STEP		First							Second	Third	
		All miRNA associated with clinical endpoints according to SAM							Results from SAM controlled in single parameter Student's <i>t</i> test	Results from Investigation cohort validated in larger independent cohort	
		Investigation cohort							Validation cohort		
miRNA	<i>n</i>	T	N	M	TRG	ypT	ypN	P-value (Student's <i>t</i> test)	<i>n</i>	P-value (Student's <i>t</i> test)	
All miRNA highlighted by SAM	Selected for further validation	hsa-miR-141-3p	20		0.771				0.010	64	<0.000
		hsa-miR-375	24		0.646				0.017	63	<0.000
		hsa-miR-301a-3p	21				1.300		0.024	64	0.593
		hsa-miR-423-5p	29			-1.273			0.008	64	0.160
		hsa-miR-431-5p	20			0.800			0.005	61	0.646
		hsa-miR-29a-3p	29				0.935		0.730	64	0.725
	hsa-miR-1	18				1.143		0.118			
	hsa-miR-128-3p	28				1.160		0.087			
	hsa-miR-135a-5p	8			0.573			NA			
	hsa-miR-138-5p	4				1.320		NA			
	hsa-miR-186-5p	17				1.150		0.063			
	hsa-miR-193a-3p	8				1.603		NA			
	hsa-miR-204-5p	8			0.570			NA			
	hsa-miR-206	10				1.365		0.139			
	hsa-miR-29b-2-5p	7				1.324		NA			
	hsa-miR-323a-3p	8				1.402		NA			
	hsa-miR-335-5p	25		1.214				0.024			
	hsa-miR-337-5p	15			0.806			0.190			
	hsa-miR-33a-5p	27				1.250		0.104			
	hsa-miR-346	7			0.602			NA			
	hsa-miR-34c-5p	13			0.616			NA			
	hsa-miR-369-5p	3				1.415		NA			
	hsa-miR-382-5p	23				1.219		0.158			
	hsa-miR-410-3p	19			0.820			0.079			
	hsa-miR-449a	13				1.538		0.973			
	hsa-miR-450a-5p	11			0.574			NA			
	hsa-miR-491-5p	7				1.564		NA			
	hsa-miR-545-3p	13			0.602			NA			
	hsa-miR-551b-3p	17			0.827			0.499			
	hsa-miR-570-3p	3				1.333		NA			
	hsa-miR-576-5p	12				1.356		0.679			
	hsa-miR-765	6				1.362		NA			
	hsa-miR-92a-3p	29			1.244			0.178			
	hsa-miR-940	14			0.579	1.266		NA/0.206			
	hsa-miR-98-5p	22				1.113		0.159			
	SNORD49A	8				1.419		NA			

The authors would like to apologise for any inconvenience caused.